WASHINGTON (Reuters) - The Food and Drug Administration said on Monday the Roche Holding AG organ rejection drug, CellCept, boosts the risk of pregnancy loss in the first trimester and also the risk of congenital malformations.
WASHINGTON (Reuters) - The Food and Drug Administration said on Monday the Roche Holding AG organ rejection drug, CellCept, boosts the risk of pregnancy loss in the first trimester and also the risk of congenital malformations.
